首頁 > 市場調查報告書 > 製藥

癌症

軟組織肉瘤市場規模、佔有率和成長分析（按類型、診斷、治療方法、最終用戶和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1915818

軟組織肉瘤市場規模、佔有率和成長分析（按類型、診斷、治療方法、最終用戶和地區分類）—2026-2033年產業預測

Soft Tissue Sarcoma Market Size, Share, and Growth Analysis, By Type (Angiosarcoma, Epithelioid Sarcoma), By Diagnosis (Biopsy, Ultrasound Scan), By Treatment, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2026年01月02日 | 出版商:

SkyQuest | 英文 188 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球軟組織肉瘤市場規模將達到 41.1 億美元，到 2025 年將達到 44.5 億美元，到 2033 年將達到 83.6 億美元，預測期（2026-2033 年）的複合年成長率為 8.2%。

全球軟組織肉瘤市場正經歷快速成長，這主要得益於癌症發病率的上升、人們對罕見癌症疾病認知的提高以及創新治療方法的蓬勃發展。包括磁振造影（MRI）和正子斷層掃描（PET）在內的診斷技術的進步，促進了早期發現，從而改善了治療方案。大型製藥公司增加對標靶治療（例如蛋白酪氨酸激酶抑制劑和免疫療法）的投資，進一步推動了市場擴張。監管機構對加速藥物核准和孤兒藥認定的支持，促進了新型治療方法的研發。然而，挑戰依然存在，包括患者群體有限、治療費用高昂以及早期診斷的複雜性。此外，軟組織肉瘤的異質性也增加了臨床試驗的難度，而標準治療的副作用可能會影響患者的治療依從性，尤其是在缺乏專業醫療資源的低度開發地區。

全球軟組織肉瘤市場促進因素

全球軟組織肉瘤市場成長的主要驅動力是全球各類軟組織肉瘤發生率和盛行率的不斷上升。診斷技術的進步和對該疾病認知的加深，使得更多病例得以發現，從而導致對有效治療方法的需求日益成長。這種不斷成長的需求涵蓋了多種治療方法，包括手術、放射線治療、化療和創新標靶治療。隨著人們對軟組織肉瘤的認知和檢測率的持續提高，市場呈現出擴張的跡象，這反映出對能夠滿足軟組織肉瘤患者多樣化需求的先進治療方案的迫切需求。

限制全球軟組織肉瘤市場的因素

全球軟組織肉瘤市場面臨的主要障礙之一是疾病的罕見性和顯著的異質性。軟組織肉瘤包含多種組織學亞型，每種亞型都有獨特的生物學行為和不同的治療反應。這種罕見性使得進行大規模臨床試驗變得困難，並最終阻礙了有效治療方法的研發。此外，亞型間的多樣性也使得治療方案的標準化變得複雜，並導致人們對該疾病的認知存在碎片化。這種情況阻礙了研究工作，並延緩了軟組織肉瘤患者創新治療方法的進展。

全球軟組織肉瘤市場趨勢

全球軟組織肉瘤市場正經歷著向標靶治療和免疫療法的興起和應用的重大轉變，這反映了腫瘤學領域的更廣泛趨勢。這些創新治療方法透過特異性靶向癌細胞和活化免疫系統，顯著改善了患者的治療效果，與傳統化療相比，在提高療效的同時，也可能降低毒性。隨著醫療機構和研究人員更加重視個人化醫療，對這些先進治療方法的需求也不斷成長，從而推動了研發投入。這種轉變不僅帶來了更多更優的治療選擇，也促進了軟組織肉瘤治療中以病人為中心的理念。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Eli Lilly and Company（United States）
Janssen Global Services, LLC（United States）
Bayer AG（Germany）
Bristol-Myers Squibb（BMS）（United States）
Merck & Co., Inc.（United States）
Eisai Co., Ltd.（Japan）
Novartis International AG（Switzerland）
Pfizer Inc.（United States）
Roche Holding AG（Switzerland）
AstraZeneca PLC（United Kingdom）
Takeda Pharmaceutical Company Limited（Japan）
Immunomedics（United States）
Adaptimmune Therapeutics plc（United Kingdom）
Blueprint Medicines（United States）
Epizyme, Inc.（United States）
Ipsen SA（France）
Jazz Pharmaceuticals plc（Ireland）
GE HealthCare（United States）
Siemens Healthineers（Germany）
Varian Medical Systems（United States）

結論與建議

簡介目錄

Product Code: SQMIG35I2479

Global Soft Tissue Sarcoma Market size was valued at USD 4.11 Billion in 2024 and is poised to grow from USD 4.45 Billion in 2025 to USD 8.36 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).

The global market for soft tissue sarcoma is experiencing rapid growth driven by the rising incidence of cancer, heightened awareness of rare oncological conditions, and a robust pipeline of innovative therapies. Advancements in diagnostic technologies, including MRI and PET scans, facilitate early detection, leading to improved treatment options. Increased investment from major pharmaceutical companies in targeted therapies, such as tyrosine kinase inhibitors and immunotherapies, further propels market expansion. Regulatory support for faster drug approvals and orphan designations has encouraged the development of novel treatments. However, challenges persist, including a limited patient population, high treatment costs, and complexities in early diagnosis. Additionally, the heterogeneous nature of soft tissue sarcomas complicates clinical trials, while side effects from standard treatments may hinder adherence, especially in developing regions lacking specialized healthcare.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Soft Tissue Sarcoma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Soft Tissue Sarcoma Market Segments Analysis

Global Soft Tissue Sarcoma Market is segmented by Type, Diagnosis, Treatment, End User and region. Based on Type, the market is segmented into Angiosarcoma, Epithelioid Sarcoma, Gastrointestinal Stromal Tumor (GIST) and Others. Based on Diagnosis, the market is segmented into Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI) and Others. Based on Treatment, the market is segmented into Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy and Surgery. Based on End User, the market is segmented into Hospitals and Clinics, Cancer Research Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Soft Tissue Sarcoma Market

The Global Soft Tissue Sarcoma market is primarily driven by the rising incidence and prevalence of various forms of soft tissue sarcoma worldwide. Enhanced diagnostic techniques and a deeper understanding of the disease have contributed to the identification of more cases, consequently increasing the demand for effective treatment options. This growing need encompasses a range of therapeutic approaches, including surgical procedures, radiation therapy, chemotherapy, and innovative targeted therapies. As awareness and detection continue to improve, the market is poised for expansion, reflecting the urgency for advanced treatment solutions that cater to the diverse needs of patients diagnosed with soft tissue sarcoma.

Restraints in the Global Soft Tissue Sarcoma Market

One of the significant obstacles facing the global soft tissue sarcoma market is the uncommon nature and considerable heterogeneity of the disease. Soft tissue sarcoma comprises various histological subtypes, each displaying distinct biological behaviors and varying responses to treatment. This rarity presents challenges in organizing large-scale clinical trials and ultimately hinders the development of effective therapies. Furthermore, the diversity among subtypes complicates the standardization of treatment approaches, resulting in a fragmented understanding of the disease. This situation complicates research efforts and slows down advancements in innovative solutions for patients affected by soft tissue sarcoma.

Market Trends of the Global Soft Tissue Sarcoma Market

The Global Soft Tissue Sarcoma market is witnessing a significant shift towards the emergence and adoption of targeted therapies and immunotherapies, reflecting a broader trend in oncology. These innovative treatment modalities are transforming patient outcomes by specifically targeting cancer cells and leveraging the immune system, offering enhanced efficacy with potentially reduced toxicity compared to conventional chemotherapy. As healthcare providers and researchers focus on personalized medicine, the demand for these advanced therapies is increasing, driving investments in research and development. This shift not only fosters improved treatment options but also encourages a more patient-centric approach in the management of soft tissue sarcoma.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Technology Assessment

Global Soft Tissue Sarcoma Market Size by Type & CAGR (2026-2033)

Market Overview
Angiosarcoma
Epithelioid Sarcoma
Gastrointestinal Stromal Tumor (GIST)
Others

Global Soft Tissue Sarcoma Market Size by Diagnosis & CAGR (2026-2033)

Market Overview
Biopsy
Ultrasound Scan
Magnetic Resonance Imaging (MRI)
Others

Global Soft Tissue Sarcoma Market Size by Treatment & CAGR (2026-2033)

Market Overview
Targeted Therapy
Chemotherapy
Anti-Angiogenesis Drugs
Radiation Therapy
Surgery

Global Soft Tissue Sarcoma Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals and Clinics
Cancer Research Centers
Others

Global Soft Tissue Sarcoma Market Size & CAGR (2026-2033)

North America (Type, Diagnosis, Treatment, End User)
- US
- Canada
Europe (Type, Diagnosis, Treatment, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Diagnosis, Treatment, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Diagnosis, Treatment, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Diagnosis, Treatment, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Global Services, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb (BMS) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Immunomedics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adaptimmune Therapeutics plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Blueprint Medicines (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Epizyme, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jazz Pharmaceuticals plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE HealthCare (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Varian Medical Systems (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments